ArticleBiomolecules & biomedicine2025
EPAS1 amplifies asthma pathogenesis through JAK2/STAT3-mediated ferroptosis and inflammation.
Article in Biomolecules & biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- NO modulates human airway smooth muscle function by altering glucose-6-phosphate dehydrogenase effects on sGC function in asthma.Redox biology · 2026Article
- Ononin combined withBiochemistry and biophysics reports · 2026Article
- Ferroptosis as an Emerging Therapeutic Target in Allergic Diseases.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a chronic respiratory disorder marked by airway hyperresponsiveness and inflammation, yet the specific molecular mechanisms driving these processes remain only partially understood. This study aims to better understand how the JAK2/STAT3/EPAS1 axis regulates inflammation and ferroptosis in asthma. Asthma-related datasets were retrieved from the Gene Expression Omnibus (GEO) database, and differentially expressed genes (DEGs) were identified. Weighted Gene Co-expression Network Analysis (WGCNA) was used to detect gene modules associated with asthma. A protein-protein interaction (PPI) network was then constructed by intersecting WGCNA-derived genes with ferroptosis-related genes to identify key hub genes. The diagnostic value of these ferroptosis-associated genes was evaluated using Receiver Operating Characteristic (ROC) curve analysis. Additionally, immune cell infiltration in asthma patients was analyzed using the Immune Cell AI database in relation to ferroptosis-related genes. Functional experiments at the cellular level were conducted to assess the effects of key genes on cell viability, inflammation, and ferroptosis. Bioinformatics analysis identified 1,698 DEGs linked to asthma. Five hub genes with clinical diagnostic value- Endothelial PAS Domain Protein 1 (EPAS1), STAT3, G6PD, CYBB, and CBS-were identified. Immune analysis revealed that EPAS1 is closely associated with immune cell infiltration in asthma. Functional experiments further demonstrated that the JAK2/STAT3 axis promotes ferroptosis and inflammatory responses by upregulating EPAS1 expression. Notably, these findings highlight the JAK2/STAT3/EPAS1 axis as a potential therapeutic target for asthma, offering new insights into its molecular mechanisms and identifying novel biomarkers for diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.